← Back to Screener
Elutia Inc. Class A Common Stock (ELUT)
Price$1.00
Value ScoreB
Growth ScoreF
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)55.26%
Price vs S&P 500 (4W)-1.11%
VGM Score44.26
Market Capitalization$44.15M
P/E Ratio (Annual)0.83x
All Metrics
Book Value / Share (Quarterly)$0.51
P/TBV (Annual)1.13x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-37.01%
Cash Flow / Share (Quarterly)$-1.04
Price vs S&P 500 (YTD)35.95%
Gross Margin (TTM)54.02%
Net Profit Margin (TTM)312.09%
EPS (TTM)$1.16
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$1.16
Revenue Growth (5Y)-22.04%
EPS (Annual)$1.29
ROI (Annual)192.90%
Gross Margin (Annual)53.66%
Net Profit Margin (5Y Avg)-11.71%
Cash / Share (Quarterly)$0.64
P/E Basic Excl Extra (TTM)0.89x
Revenue Growth QoQ (YoY)-48.36%
P/E Normalized (Annual)0.83x
ROA (Last FY)85.61%
Revenue Growth TTM (YoY)-32.64%
EBITD / Share (TTM)$-0.61
Operating Margin (TTM)-175.27%
Cash Flow / Share (Annual)$-1.09
P/B Ratio1.96x
P/B Ratio (Quarterly)1.99x
Net Income / Employee (Annual)$2,135,200
EV / Revenue (TTM)0.98x
Net Interest Coverage (TTM)-1.87x
ROA (TTM)110.27%
EPS Incl Extra (Annual)$1.29
Current Ratio (Annual)2.22x
Quick Ratio (Quarterly)1.85x
3-Month Avg Trading Volume0.15M
52-Week Price Return-45.13%
P/E Incl Extra (TTM)0.89x
Revenue / Employee (TTM)$638,800
Tangible BV / Share (Quarterly)$0.48
P/S Ratio (Annual)3.59x
Asset Turnover (Annual)0.20x
52-Week High$2.64
Operating Margin (5Y Avg)-115.31%
EPS Excl Extra (Annual)$1.29
CapEx CAGR (5Y)24.00%
26-Week Price Return63.19%
Quick Ratio (Annual)2.03x
13-Week Price Return-10.03%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.05x
Enterprise Value$15.66M
Revenue / Share Growth (5Y)-41.06%
Asset Turnover (TTM)0.35x
Revenue / Employee (Annual)$491,700
Inventory Turnover (Annual)1.75x
Pretax Margin (Annual)-129.00%
Cash / Share (Annual)$0.85
3-Month Return Std Dev58.04%
Gross Margin (5Y Avg)41.02%
Net Income / Employee (TTM)$1,993,800
ROE (Last FY)192.90%
Net Interest Coverage (Annual)-4.06x
EPS Basic Excl Extra (Annual)$1.29
Receivables Turnover (TTM)6.48x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$1.16
Receivables Turnover (Annual)6.13x
ROI (TTM)252.28%
P/S Ratio (TTM)2.76x
Pretax Margin (5Y Avg)-120.13%
Revenue / Share (Annual)$0.30
Tangible BV / Share (Annual)$0.61
Price vs S&P 500 (52W)-69.49%
P/E Ratio (TTM)0.89x
Year-to-Date Return44.11%
5-Day Price Return-5.78%
EPS Normalized (Annual)$1.29
ROA (5Y Avg)-47.04%
Net Profit Margin (Annual)434.23%
Month-to-Date Return-13.91%
Cash Flow / Share (TTM)$-1.72
EBITD / Share (Annual)$-0.58
Operating Margin (Annual)-218.91%
LT Debt / Equity (Annual)0.00x
P/E Excl Extra (TTM)0.89x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$1.16
P/TBV (Quarterly)2.11x
P/B Ratio (Annual)1.07x
Inventory Turnover (TTM)2.12x
Pretax Margin (TTM)-152.29%
Book Value / Share (Annual)$0.65
Price vs S&P 500 (13W)-18.28%
Beta0.90x
Revenue / Share (TTM)$0.37
ROE (TTM)252.28%
52-Week Low$0.50
vGradeB
gGradeF
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.17est. -0.15
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.13
4.13
4.14
4.14
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ELUTElutia Inc. Class A Common Stock | B | F | D | $1.00 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Elutia Inc (formerly Aziyo Biologics Inc) is a commercial-stage regenerative medicine company that develops products to improve surgical outcomes and reduce complications associated with implantable medical devices. The company operates three segments—Device Protection, Women's Health, and Cardiovascular—with Women's Health as its primary revenue driver. Its product portfolio addresses unmet clinical needs including scar tissue formation, implant rejection, capsular contraction, and device-related complications.